Report warns NHS faces AI negligence claims

Doctors and the NHS could face medical negligence claims for patient harm caused by artificial intelligence systems used in diagnosis or treatment planning, according to a warning issued to ministers by the Medical Protection Society on 9 June. The report says current law leaves clinicians and health services exposed even when an AI tool is the source of the mistake.

The immediate consequence is practical, not theoretical: if clinicians believe they will carry the blame for an opaque system’s error, adoption of new tools may slow. That matters for an NHS under heavy pressure to modernise, and it lands as health leaders continue to promote digital medicine alongside wider investment in NHS-linked health innovation hubs.

Background

The warning comes from the Medical Protection Society, a long-established defence organisation for doctors and other healthcare professionals. Its argument is simple. AI is entering clinics faster than liability law is adapting, and the present framework may leave the human clinician as the obvious defendant when a patient is harmed. In medicine, that risk is rarely abstract. A missed cancer, a delayed stroke diagnosis, a treatment recommendation that ignores a contraindication — each can lead to severe injury or death.

That legal exposure sits inside a broader push to bring algorithmic tools into healthcare. Across the NHS and other health systems, AI has been explored for imaging, triage, risk prediction and administrative support. Some systems are regulated as medical devices, with oversight shaped in the UK by the Medicines and Healthcare products Regulatory Agency; others raise live questions about software updates, transparency and real-world monitoring. Peer review can test a model in a paper. It does not guarantee safe performance in a busy emergency department on a wet Monday in February.

The basic legal terrain is also old compared with the technology. Negligence claims in medicine generally turn on whether care fell below the expected standard and whether that failure caused harm. If a doctor relies on an AI output and the output is wrong, the doctor may still be asked why they trusted it. If an NHS trust deploys the system, the trust may be asked whether procurement, governance and supervision were adequate. Blaming the machine won’t answer either question.

And this is where the Medical Protection Society’s warning lands hardest. It isn’t claiming AI has no place in care. It is saying ministers should overhaul the law so liability better reflects who designed, sold, validated and implemented the technology, rather than letting risk settle by default on the clinician nearest the patient.

What this means

The near-term effect may be more caution from doctors, hospital legal teams and indemnity advisers. That doesn’t mean AI use will stop. It means clinicians may be less willing to act on algorithmic recommendations without independent checking, especially in high-stakes fields such as oncology, radiology and emergency medicine. In some settings, that could blunt any efficiency gains promised by developers. Readers have already seen how medicine struggles to balance speed with evidence in areas from rehabilitation to cancer care, including early rehab after brain injury and the tempered optimism in recent cancer data.

There is also a policy choice hiding in plain sight. If ministers want clinicians to adopt AI responsibly, they need legal clarity on accountability, procurement standards, audit trails and post-market surveillance. Without that, the NHS could end up paying twice — once for expensive tools and again for the litigation that follows preventable failures. The result: a technology agenda marketed as efficient may become administratively defensive.

Still, one clean point should not be lost. The report is a warning about legal exposure, not evidence that AI errors are already driving a wave of successful claims.

That distinction matters because health technology debates often run ahead of the evidence. We are still dealing with a patchy record on how clinical AI performs across different hospitals, patient groups and real-world workflows. Some tools have shown promise in tightly defined tasks; others have stumbled when moved from development data to routine care. The scientific literature on AI in medicine is large, but replication and external validation are inconsistent, a problem documented repeatedly in journals indexed by PubMed and discussed by editors at Nature. If law remains vague while evidence remains uneven, clinicians will practice with one eye on the patient and the other on the claim form.

The winners from reform would be clear: patients, who need transparent accountability; clinicians, who need defined responsibilities; and health systems, which need confidence that safe adoption won’t create open-ended legal jeopardy. The losers would be any vendor hoping a “black box” can enter frontline medicine without hard scrutiny. In healthcare, opacity is not innovation. It is a risk factor.

Blaming the machine won’t answer the legal questions that follow a patient’s injury.

What happens next is specific. Ministers will now face pressure to respond to the Medical Protection Society’s call for legal reform, and NHS organisations weighing new AI deployments will be watching for any signal on liability, regulation and indemnity. Until that arrives, every trust considering a new clinical algorithm is likely to ask the same hard question first: if the software is wrong, who is in the dock?